Article info
Original Articles: Ovarian Cancer
Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy: A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
- Address correspondence and reprint requests to Felix Hilpert, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Michaelisstrasse 16, 24105 Kiel, Germany. E-mail: fhilpert{at}email.uni-kiel.de.
Citation
Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy: A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Publication history
- First published January 1, 2009.
Online issue publication
January 01, 2009
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2009 Lippincott Wiliams & Wilkins